Erratum to: Sorafenib-Associated Facial Acneiform Eruption

Erratum to: Dermatol Ther (Heidelb) (2014) 5(1) DOI 10.1007/s13555-014-0067-9

The author of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following correction.

On page 6 there is to be a change to the labelling of Table 2 footnotes. “Table 2 Characteristics of patients with sorafenib-associated facial acneiform facial eruptions” is to be replaced with the following:

Table 2.

Characteristics of patients with sorafenib-associated facial acneiform facial eruptions

Case [Ref.]	1 [37]	2 [38] C1	3 [39]	4 [38] C2	5 CR
Age (years)	42	51	52	65	79
Race	NS	White	White	White	Asian
Sex	Female	Male	Male	Male	Male
Ca	LEH	mRCC	mRC	mRCC	HCC
FAL	+	+b	+	+d	+f
OSAL	Trunk (upper)	Arms, axillae, back (upper), chest (upper)	Genital area, neck, scalp	–	–
Symptoms	–	Burning sensation, oiliness (increased), pruritus	Pain	Oiliness (increased)	–
Lesion morph	Papules, pustules	Open comedones = closed comedones (Ca-L)	Papules, pustules	Open comedones = closed comedones (Ca-L)	Open comedones > closed comedones (Ca-L)
Soraf dose	400 mg BID × 4 weeks, then 800 mg BID	400 mg BID	600 mg QD	400 mg BID	400 mg BID
Onseta	4.1	6	4	8	1.3
OSCAE	NS	NS	Alopecia, HFSR, SFFH, Sp-l	NS	Alopecia, HFSR, ISK, SD-LE, xerosis
Treatment	Cleared 2 weeks after Soraf dose lowered to 400 mg BID	70% improvement after BP × 2 months	Improvement after oral tetracycline and topical: BP, EES, Flu, and Met	Tret 0.05%	Clin, Tret 0.025%
Comment	Pt died 2 months after lowering dose of Soraf from cancer prog	c	Soraf stopped for surgery; ACE reappeared when restarted soraf	Exposure to Agent Orange in Vietname	Lesions slowly resolving with topical therapy after stop Soraf

ACE acneiform eruption, BID twice daily, BP benzoyl peroxide, Ca cancer, Ca-L chloracne-like, C case, Clin clindamycin 1% solution twice daily, CR current report, EES erythromycin, FAL facial acneiform lesions, Flu fluocinonide cream, HCC hepatocellular carcinoma, HFSR hand–foot skin reaction, ISK inflamed seborrheic keratosis, LEH liver epithelioid hemangioendothelioma, Met metronidazole, mRC metastatic renal carcinoma, mRCC metastatic renal cell carcinoma, NS not stated, OSAL other sites of acneiform lesions, OSCAE other sorafenib-associated cutaneous adverse events, prog progression, Pt patient, QD daily, SD-LE seborrheic dermatitis-like eruption, SFFH spiny filiform follicular hyperkeratosis, soraf sorafenib, Sp-l sandpaper-like skin texture, Tret 0.025% tretinoin 0.025% cream each evening, Tret 0.05% tretinoin 0.05% cream each evening, + present, − absent

^aNumber of weeks on sorafenib prior to appearance of acneiform eruption

^bThe facial acneiform lesions were located on bilateral malar cheeks and postauricular areas

^cA skin biopsy of an acneiform lesion showed milia-like cyst with a sparse lymphocytic inflammatory dermal infiltrate

^dThe facial acneiform lesions were located on the nose and bilateral malar cheeks, temples and postauricular areas

^eThe patient did not return for follow up examination

^fThe facial acneiform lesions were located on bilateral malar cheeks, preauricular areas, ears and postauricular areas